End-stage renal disease. ?End-stage renal disease
Conditions
Interventions
Intervention 1: Recombinant Hepatitis B vaccine (Euvax B®) 2.5 µg at 2 different sites (totally 5µg) every 2 weeks untill 2 months and then monthly until end of the forth month and one injection at th
Prevention
Recombinant Hepatitis B vaccine (Euvax B®) 2.5 µg at 2 different sites (totally 5µg) every 2 weeks untill 2 months and then monthly until end of the forth month and one injection at the sixth month (4
Recombinant Hepatitis B vaccine (Euvax B®) 40 µg at months: 0-1-2-6 (160 µg total dose) by intramuscular injection.
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: CRF patients who are under dialysis (hemodyalisis or peritoneal dialysis) in Bualisina dialysis centre, HBsAg lower than 10 U/ml and at least a previous course of hepatitis B vaccination. Exclusion criteria: Presence of malignancy, severe malnutrition, positive HBsAg, kidney transplantation, immunocompromising disease such as AIDS.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti HBs antibody titre. Timepoint: Before intervention, 7, 12, and 18 months after intervention. Method of measurement: anti HBs antibody titre measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehzad Bijani
Qazvin University of Medical Sciences
Outcome results
None listed